Log in

Solid Biosciences Stock Forecast, Price & News

-0.07 (-3.04 %)
(As of 09/22/2020 12:00 AM ET)
Today's Range
Now: $2.23
50-Day Range
MA: $2.46
52-Week Range
Now: $2.23
Volume281,277 shs
Average Volume326,371 shs
Market Capitalization$102.81 million
P/E RatioN/A
Dividend YieldN/A
Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
Solid Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:SLDB



Sales & Book Value

Annual SalesN/A
Book Value$1.74 per share


Net Income$-117,220,000.00


Market Cap$102.81 million
Next Earnings Date11/10/2020 (Estimated)
-0.07 (-3.04 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SLDB News and Ratings via Email

Sign-up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions

How has Solid Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Solid Biosciences' stock was trading at $3.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SLDB stock has decreased by 29.0% and is now trading at $2.23.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Solid Biosciences?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Solid Biosciences

When is Solid Biosciences' next earnings date?

Solid Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Solid Biosciences

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc (NASDAQ:SLDB) released its quarterly earnings results on Thursday, March, 12th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.04.
View Solid Biosciences' earnings history

What price target have analysts set for SLDB?

6 analysts have issued 1 year price objectives for Solid Biosciences' shares. Their forecasts range from $2.00 to $22.00. On average, they anticipate Solid Biosciences' stock price to reach $8.00 in the next year. This suggests a possible upside of 258.7% from the stock's current price.
View analysts' price targets for Solid Biosciences

Are investors shorting Solid Biosciences?

Solid Biosciences saw a drop in short interest in August. As of August 14th, there was short interest totaling 1,820,000 shares, a drop of 12.5% from the July 30th total of 2,080,000 shares. Based on an average daily trading volume, of 288,800 shares, the days-to-cover ratio is presently 6.3 days. Approximately 6.0% of the company's shares are sold short.
View Solid Biosciences' Short Interest

Who are some of Solid Biosciences' key competitors?

What other stocks do shareholders of Solid Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include Amarin (AMRN), Inovio Pharmaceuticals (INO), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Verastem (VSTM) and Agile Therapeutics (AGRX).

Who are Solid Biosciences' key executives?

Solid Biosciences' management team includes the following people:
  • Dr. Andrey Juan Zarur, Co-Founder & Chairman of Directors (Age 48)
  • Mr. Ilan Ganot, Co-founder, Pres, CEO & Director (Age 45)
  • Mr. Pedro Alvaro Amorrortu, Chief Operating Officer (Age 47)
  • Dr. Carl Ashley Morris, Chief Scientific Officer (Age 49)
  • Dr. Andrey Zarur Ph.D., Co-Founder & Chairman of Directors (Age 48)

When did Solid Biosciences IPO?

(SLDB) raised $130 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 7,000,000 shares at $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers.

What is Solid Biosciences' stock symbol?

Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."

Who are Solid Biosciences' major shareholders?

Solid Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Ikarian Capital LLC (1.71%), Two Sigma Advisers LP (0.32%), Bridgeway Capital Management Inc. (0.31%), Jacobs Levy Equity Management Inc. (0.24%), Charles Schwab Investment Management Inc. (0.23%) and Bank of New York Mellon Corp (0.17%). Company insiders that own Solid Biosciences stock include Boxer Capital, Llc, Carl Ashley Morris, Ilan Ganot, Joel Solomon Zev Schneider, Jorge Armando Quiroz, Juan Andrey Zarur, Life Sciences Maste Perceptive, Matthew Bennett Arnold and Pedro Alvaro Amorrortu.
View institutional ownership trends for Solid Biosciences

Which institutional investors are selling Solid Biosciences stock?

SLDB stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, PDT Partners LLC, UBS Group AG, Matisse Capital, Tudor Investment Corp Et Al, and Bank of New York Mellon Corp. Company insiders that have sold Solid Biosciences company stock in the last year include Carl Ashley Morris, Ilan Ganot, and Joel Solomon Zev Schneider.
View insider buying and selling activity for Solid Biosciences

Which institutional investors are buying Solid Biosciences stock?

SLDB stock was bought by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Jacobs Levy Equity Management Inc., Two Sigma Advisers LP, Russell Investments Group Ltd., Jane Street Group LLC, Charles Schwab Investment Management Inc., Engineers Gate Manager LP, and ProShare Advisors LLC.
View insider buying and selling activity for Solid Biosciences

How do I buy shares of Solid Biosciences?

Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Solid Biosciences' stock price today?

One share of SLDB stock can currently be purchased for approximately $2.23.

How big of a company is Solid Biosciences?

Solid Biosciences has a market capitalization of $102.81 million. The company earns $-117,220,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. Solid Biosciences employs 111 workers across the globe.

What is Solid Biosciences' official website?

The official website for Solid Biosciences is www.solidbio.com.

How can I contact Solid Biosciences?

Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680.

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.